- Home
- SSBK vs DSGN Comparison
SSBK vs DSGN Comparison
Compare SSBK & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSBK
- DSGN
- Stock Information
- Founded
- SSBK 2007
- DSGN 2017
- Country
- SSBK United States
- DSGN United States
- Employees
- SSBK N/A
- DSGN N/A
- Industry
- SSBK Commercial Banks
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- SSBK Finance
- DSGN Health Care
- Exchange
- SSBK Nasdaq
- DSGN Nasdaq
- Market Cap
- SSBK 330.0M
- DSGN 348.2M
- IPO Year
- SSBK 2021
- DSGN 2021
- Fundamental
- Price
- SSBK $34.63
- DSGN $4.87
- Analyst Decision
- SSBK Buy
- DSGN Hold
- Analyst Count
- SSBK 1
- DSGN 3
- Target Price
- SSBK $36.00
- DSGN $7.00
- AVG Volume (30 Days)
- SSBK 24.0K
- DSGN 220.6K
- Earning Date
- SSBK 01-21-2025
- DSGN 03-18-2025
- Dividend Yield
- SSBK 1.04%
- DSGN N/A
- EPS Growth
- SSBK 3.86
- DSGN N/A
- EPS
- SSBK 3.67
- DSGN N/A
- Revenue
- SSBK $94,140,000.00
- DSGN N/A
- Revenue This Year
- SSBK N/A
- DSGN N/A
- Revenue Next Year
- SSBK $11.75
- DSGN N/A
- P/E Ratio
- SSBK $9.29
- DSGN N/A
- Revenue Growth
- SSBK 13.56
- DSGN N/A
- 52 Week Low
- SSBK $22.13
- DSGN $2.25
- 52 Week High
- SSBK $39.16
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- SSBK 55.59
- DSGN 42.19
- Support Level
- SSBK $33.05
- DSGN $3.71
- Resistance Level
- SSBK $35.28
- DSGN $6.81
- Average True Range (ATR)
- SSBK 1.08
- DSGN 0.50
- MACD
- SSBK 0.28
- DSGN -0.10
- Stochastic Oscillator
- SSBK 85.24
- DSGN 37.42
About SSBK Southern States Bancshares Inc.
Southern States Bancshares Inc is a full-service community banking institution, that offers an array of deposit, loan, and other banking-related products and services to businesses and individuals in communities. It has three portfolio segments Real estate, Commercial and industrial, Consumer and other.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.